Avidity Up 33% on Rare Muscle Disease Study Results - Arcutis Biotherapeutics (NASDAQ:ARQT), Heron Therapeutics (NASDAQ:HRTX)

Avidity Biosciences (NASDAQ: RNA) announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlosiran (del-brax, or formerly AOC 1020) in facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disease of the muscles.

Related Keywords

Colorado ,United States ,Marinus Pharmaceuticals ,Arcutis Biotherapeutic ,Heron Therapeutics ,Arcutis Biotherapeutics ,Earnings Of Marinus Pharmaceuticals ,Society International Research Congress ,Avidity Biosciences Inc ,Avidity Bioscience ,International Research Congress ,Avidity Biosciences ,Zacks Rank ,Marinus Pharmaceutical ,Heron Therapeutic ,